全口服IBiRd方案治疗复发难治性多发性骨髓瘤的疗效及安全性分析  

Efficacy and safety analysis of total oral medication IBiRd regimen in the treatment of patients with relapsed/refractory multiple myeloma

作　　者：王秀峰 李婷[2] 字友梅[1] 刘宪凯 杨满[1] 吕国庆[1] 吴隼[1] 黄琰[1] WANG Xiufeng;LI Ting;ZI Youmei;LIU Xiankai;YANG Man;LYU Guoqing;WU Sun;HUANG Yan(Department of Hematology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang Key Laboratory for Molecular Diagnosis and Therapy of Lymphoma,Henan Weihui 453100,China;Department of Blood Purification,the First Affiliated Hospital of Xinxiang Medical University,Henan Weihui 453100,China)

机构地区：[1]新乡医学院第一附属医院血液科,新乡市淋巴瘤分子诊疗重点实验室,河南卫辉453100 [2]新乡医学院第一附属医院血液净化室,河南卫辉453100

出　　处：《现代肿瘤医学》2023年第19期3644-3648,共5页Journal of Modern Oncology

基　　金：河南省医学科技攻关计划联合共建项目(编号:LHGJ20210533);河南省新乡市科技攻关项目(编号:GG2020029)。

摘　　要：目的:评价全口服IBiRD(伊沙佐米+克拉霉素+来那度胺+地塞米松)方案化疗对复发难治多发性骨髓瘤的疗效及安全性。方法:回顾性分析2020年01月01日至2021年12月31日在我院接受IBiRD方案化疗的28例复发难治多发性骨髓瘤患者临床资料,总结其治疗2周期后的有效率和不良反应,并进行分析。结果:28例患者治疗2周期后进行疗效评价,临床获益率78.6%,客观缓解率50.0%,其中非常好的部分缓解率14.3%,部分缓解率35.7%,微小缓解率28.6%,不良反应轻微,主要为乏力、纳差、腹泻和血液学毒性。结论:全口服IBiRD方案是一种全有效的口服治疗复发难治性骨髓瘤的方案,且不良反应轻微。Objective:To evaluate the efficacy and safety of total oral medication IBiRd regimen(Ixazomib+clarithromycin+lenalidomide+dexamethasone)on relapsed/refractory multiple myeloma.Methods:Retrospectively analyze 28 cases of relapsed/refractory multiple myeloma in our hospital from January 1,2020 to December 31,2021.The efficacy and adverse reactions after 2 cycles of treatment were summarized and analyzed.Results:28 patients were evaluated after 2 cycles of treatment.The clinical benefit rate was 78.6%.The objective response rate was 50%,among which very good partial response rate was 14.3%,partial response rate was 35.7%,minimal response rate was 28.6%,and adverse reactions were mild,mainly including fatigue,appetite loss,diarrhea and hematologic toxicity.Conclusion:The all-oral IBiRD regimen is an effective all-oral regimen for the treatment of relapsed and refractory myeloma with mild adverse effects.

关 键 词：IRD 克拉霉素 复发难治性多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]